Sign inJoin waitlistJoin the waitlist

Nilofer Azad

Co-Director, Medical Oncology T32 · Johns Hopkins University School of Medicine

Credentials: · · · ·

History

Medical Oncology T32 · Johns Hopkins University School of Medicine
Present

Medical Oncology
2004–2006
Internal Medicine
2001–2004
Baylor College of Medicine
1997–2001

Research

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 7,710 citations
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science · 2017 · 5,443 citations
Detection of circulating tumor DNA in early- and late-stage human malignancies
Science Translational Medicine · 2014 · 3,962 citations

Elizabeth Jaffee
27 papers
Mark Yarchoan
27 papers · 2 as a fellow
Daniel Laheru
26 papers
MB
Marina Baretti
19 papers · 15 as a resident
Robert Anders
19 papers
DL
Dung Le
18 papers
JH
Joseph Herman
17 papers
Lei Zheng
14 papers
LD
Luis Diaz
14 papers
Nita Ahuja
14 papers
Ross Donehower
13 papers
AJ
Ana De Jesus-Acosta
11 papers

Grants

Optimization of an Active Mutant KRAS Peptide Vaccine in Colorectal Cancer
National Cancer Institute · R01
Contact PI · $1.2M · Johns Hopkins University
2025–2029
Molecular Targets for Cancer Detection and Treatment
National Cancer Institute · T32
PI · $3.1M · Johns Hopkins University
1979–2027
Transforming Human Pancreatic Cancer Into An Immunologic Disease
National Cancer Institute · P01
Project lead · $1.5M · Johns Hopkins University
2021–2027
Regional Oncology Research Center
National Cancer Institute · P30
Project lead · $764.2K · Johns Hopkins University
1997–2027

Clinical trials

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Principal investigator · Recruiting · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024–2030
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Principal investigator · Recruiting · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2022–2031
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2021–2026
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Principal investigator · Active not recruiting · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020–2027